Drugs / HS_SW01 cells injection
last change Apr 2026 re-read 3 minutes ago

HS_SW01 cells injection

Cell therapy

Developed for
ankylosing spondylitis
Investigated by
Shenzhen Huishan Biotechnology Co., Ltd. · Southern Medical University, China

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07534644 Apr 2026 → Dec 2027 expected ankylosing spondylitis Shenzhen Huishan Biotechnology Co., Ltd. Not yet recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HS_SW01 cells injection ClinicalTrials.gov intervention name — accepted as the source's own label NCT07534644 ↗
Modality Cell therapy “Umbilical Cord Mesenchymal Stem Cells (UC-MSC)” NCT07534644 ↗
Route Intravenous “single intravenous infusion” NCT07534644 ↗